Journal article 280 views 10 downloads
Breastfeeding, pregnancy, medicines, neurodevelopment, and population databases: the information desert
International Breastfeeding Journal, Volume: 17, Issue: 1
Swansea University Authors: Sue Jordan , Sophia Komninou , Naomi Marfell
PDF | Version of Record
© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International LicenseDownload (2.05MB)
DOI (Published version): 10.1186/s13006-022-00494-5
BackgroundThe pharmacoepidemiology of the long-term benefits and harms of medicines in pregnancy and breastfeeding has received little attention. The impact of maternal medicines on children is increasingly recognised as a source of avoidable harm. The focus of attention has expanded from congenital...
|Published in:||International Breastfeeding Journal|
Springer Science and Business Media LLC
Check full text
No Tags, Be the first to tag this record!
BackgroundThe pharmacoepidemiology of the long-term benefits and harms of medicines in pregnancy and breastfeeding has received little attention. The impact of maternal medicines on children is increasingly recognised as a source of avoidable harm. The focus of attention has expanded from congenital anomalies to include less visible, but equally important, outcomes, including cognition, neurodevelopmental disorders, educational performance, and childhood ill-health. Breastfeeding, whether as a source of medicine exposure, a mitigator of adverse effects or as an outcome, has been all but ignored in pharmacoepidemiology and pharmacovigilance: a significant ‘blind spot’.Whole-population data on breastfeeding: why we need themOptimal child development and maternal health necessitate breastfeeding, yet little information exists to guide families regarding the safety of medicine use during lactation. Breastfeeding initiation or success may be altered by medicine use, and breastfeeding may obscure the true relationship between medicine exposure during pregnancy and developmental outcomes. Absent or poorly standardised recording of breastfeeding in most population databases hampers analysis and understanding of the complex relationships between medicine, pregnancy, breastfeeding and infant and maternal health. The purpose of this paper is to present the arguments for breastfeeding to be included alongside medicine use and neurodevelopmental outcomes in whole-population database investigations of the harms and benefits of medicines during pregnancy, the puerperium and postnatal period. We review: 1) the current situation, 2) how these complexities might be accommodated in pharmacoepidemiological models, using antidepressants and antiepileptics as examples; 3) the challenges in obtaining comprehensive data.ConclusionsThe scarcity of whole-population data and the complexities of the inter-relationships between breastfeeding, medicines, co-exposures and infant outcomes are significant barriers to full characterisation of the benefits and harms of medicines during pregnancy and breastfeeding. This makes it difficult to answer the questions: ‘is it safe to breastfeed whilst taking this medicine’, and ‘will this medicine interfere with breastfeeding and/ or infants’ development’?Keywords: Breastfeeding, Pharmacoepidemiology, Pharmacovigilance, Pregnancy, Child development, Adverse drug reactions
Breastfeeding; Pharmacoepidemiology; Pharmacovigilance; Pregnancy; Child development; Adverse drug reactions
College of Human and Health Sciences
This work has been undertaken under the auspices of the ConcePTION project. The ConcePTION project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 821520. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA. Funding was awarded to SJ, HD, ML, GJ, RB, CDM. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.